Table 2.

Incidence Rate Ratios for Incident End-Stage Renal Disease According to Categories of 1,5-Anhydroglucitol Level and Diabetes Status, Atherosclerosis Risk in Communities Study, United States, 1990–2013

Model	1,5-AG Without Diagnosed Diabetes				1,5-AG With Diagnosed Diabetes						P for Trend Among All Categories	P for Trend in Diabetes Categories
	≥10.0 μg/mL (n = 11,250)		<10.0 μg/mL (n = 783)		≥10.0 μg/mL (n = 421)		6.0–9.9 μg/mL (n = 162)		<6.0 μg/mL (n = 661)
	IRR	95% CI	IRR	95% CI	IRR	95% CI	IRR	95% CI	IRR	95% CI
1a	1	Referent	2.44	1.56, 3.84	6.28	4.15, 9.49	11.45b	7.00, 18.73	16.78b	12.93, 21.78	<0.001	<0.001
2c	1	Referent	2.24	1.42, 3.52	5.12	3.38, 7.77	8.80	5.34, 14.49	12.78b	9.75, 16.73	<0.001	<0.001
3d	1	Referent	1.96	1.24, 3.09	3.88	2.54, 5.93	6.97	4.21, 11.54	9.63b	7.24, 12.80	<0.001	<0.001
4e	1	Referent	1.85	1.16, 2.96	3.30	2.14, 5.09	5.93	3.56, 9.89	8.62b	6.45, 11.52	<0.001	<0.001
5af	1	Referent	1.71	1.07, 2.74	3.09	2.00, 4.78	4.63	2.69, 7.96	5.74b	3.83, 8.60	<0.001	0.007
5bg	1	Referent	1.38	0.83, 2.27	2.85	1.84, 4.42	3.99	2.33, 6.82	3.54	2.22, 5.64	<0.001	0.3

Abbreviations: 1,5-AG, 1,5-anhydroglucitol; CI, confidence interval; IRR, incidence rate ratio.

^a Model 1: no covariates (unadjusted).

^b Among those with diagnosed diabetes, P < 0.05 for the estimate for the respective category of 1,5-anhydroglucitol (6.0–9.9 μg/mL or <6.0 μg/mL) relative to ≥10.0 μg/mL.

^c Model 2 adjusted for demographics (age, sex, race).

^d Model 3: model 2 with the addition of estimated glomerular filtration rate based on creatinine and cystatin C (modeled as linear spline terms with knots at 60 mL/min/1.73 m² and 90 mL/min/1.73 m²).

^e Model 4: model 3 with the addition of hypertension, body mass index, current smoking.

^f Model 5a: model 4 with the addition of fasting glucose.

^g Model 5b: model 4 with the addition of glycated hemoglobin.